Advertisement News Archives - Page 127 of 5204 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 22, 2026

Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis

Opna Bio has received the US Food and Drug Administration’s (FDA) orphan drug designation for OPN-2853 (zavabresib), a bromodomain and extra-terminal motif (BET) small molecule inhibitor, to treat myelofibrosis.

Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis